BioSpace News Archive

CohBar, Inc., a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced that its Chief Executive Officer, Steven Engle, will present a company update at the BIO-Europe Conference, being held virtually on October 26 - 29, 2020.

Accuray Incorporated will report financial results for the first quarter of fiscal year 2021, ended September 30, 2020, after the market close on Thursday, October 29, 2020.

Invacare Corporation announces that it will release its financial results for the third quarter ended September 30, 2020, after the market closes on Thursday, October 29, 2020.

Revelation Biosciences Inc., a clinical stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced the appointment of Jess Roper to the Company’s Board of Directors.

Guardant Health, Inc. announced the closings of an underwritten public offering of 7,700,000 shares of its common stock, which includes full exercise of the underwriter’s option to purchase 700,000 shares, at a public offering price of $102.00 per share, before deducting underwriting discounts and commissions, all of which were sold by SoftBank Investment Advisers.

Intersect ENT, Inc., a company transforming care for patients with ear, nose and throat conditions, announced preliminary third quarter 2020 revenue and provided a business update.

Owens & Minor, Inc. plans to release financial results for the third quarter of 2020 on Monday, November 2, 2020, after trading ends on the New York Stock Exchange.

MedX Health Corp., a Company focused on becoming the global leader in teledermatology, announces that it has appointed Anthony Milonas and Wayne Cockburn as Directors of the Company, effective immediately.

Moderna, Inc. announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, October 29, 2020 to report its third quarter 2020 financial results and provide a corporate update.

Interim data from open-label extension trial showedsubstantial seizure reductions were maintainedin patients treated with FINTEPLA® for up to two years